Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KOD Kodiak Sciences	$8.62 +1.2%	$5.23	$1.92 ▼ $11.60	$449.55M	2.41	422,387 shs	601,060 shs
PGEN Precigen	$1.91 +6.1%	$1.63	$0.65 ▼ $2.17	$563.79M	1.87	2.02 million shs	4.54 million shs
PLX Protalix BioTherapeutics	$1.61 -1.8%	$1.49	$0.82 ▼ $3.10	$128.17M	-0.21	846,585 shs	936,917 shs
PRTC PureTech Health	$17.75 +1.4%	$18.26	$13.30 ▼ $25.00	$428.19M	1.12	4,444 shs	13,846 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KOD Kodiak Sciences	+6.10%	+5.32%	+88.08%	+116.24%	+244.94%
PGEN Precigen	+3.45%	-6.74%	-1.64%	+40.63%	+68.22%
PLX Protalix BioTherapeutics	+1.86%	+15.49%	+16.31%	-1.80%	+56.19%
PRTC PureTech Health	+5.10%	-2.99%	+2.41%	+9.54%	-20.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KOD Kodiak Sciences	2.5952 of 5 stars	1.0	1.0	4.6	3.3	3.3	0.0
PGEN Precigen	4.0869 of 5 stars	3.5	1.0	4.7	3.1	1.7	0.6
PLX Protalix BioTherapeutics	3.6253 of 5 stars	3.5	3.0	0.0	3.4	1.7	1.9
PRTC PureTech Health	2.1533 of 5 stars	3.8	3.0	0.0	2.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KOD Kodiak Sciences	2.00	Hold	$9.00	4.41% Upside
PGEN Precigen	3.00	Buy	$6.00	214.14% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	831.68% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	153.59% Upside

Current Analyst Ratings Breakdown

Latest PLX, KOD, PGEN, and PRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A
PGEN Precigen	$3.92M	143.82	N/A	N/A	$0.13 per share	14.69
PLX Protalix BioTherapeutics	$59.76M	2.14	$0.09 per share	17.80	$0.47 per share	3.43
PRTC PureTech Health	$4.83M	88.65	$2.47 per share	7.19	$17.04 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	5.19	N/A	-21.03%	-30.89%	-11.74%	N/A
PRTC PureTech Health	$27.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)

Latest PLX, KOD, PGEN, and PRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	-$1.03	-$0.02	-$1.03	N/A	N/A
8/12/2025	Q2 2025	PGEN Precigen	-$0.14	-$0.11	+$0.03	-$0.09	$0.67 million	$0.86 million
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KOD Kodiak Sciences	N/A	4.62	4.62
PGEN Precigen	N/A	3.53	3.53
PLX Protalix BioTherapeutics	N/A	1.98	1.27
PRTC PureTech Health	N/A	9.33	9.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KOD Kodiak Sciences	89.06%
PGEN Precigen	33.51%
PLX Protalix BioTherapeutics	16.53%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
KOD Kodiak Sciences	45.90%
PGEN Precigen	47.10%
PLX Protalix BioTherapeutics	6.50%
PRTC PureTech Health	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
PRTC PureTech Health	100	24.13 million	22.85 million	Not Optionable

PLX, KOD, PGEN, and PRTC Headlines

Recent News About These Companies

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

August 13 at 12:16 PM | businesswire.com

PureTech Health plc: PureTech Announces Board Change

July 31, 2025 | finanznachrichten.de

PureTech Health (NASDAQ:PRTC) Shares Down 7.3% - Here's What Happened

July 23, 2025 | marketbeat.com

PureTech CEO Bharatt Chowrira steps down

July 16, 2025 | thepharmaletter.comT

PureTech Health CEO Bharatt Chowrira Resigns

July 16, 2025 | marketwatch.com

PureTech Announces Leadership Transition

July 16, 2025 | businesswire.com

PureTech Health announces board chair Raju Kucherlapati steps down

July 10, 2025 | investing.com

PureTech Health plc (PRTC) Income Statement - Yahoo Finance

July 9, 2025 | finance.yahoo.com

PureTech Announces Board Change

July 8, 2025 | businesswire.com

Why This Biotech Stock Just Doubled In A Single Day

June 26, 2025 | benzinga.com

PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial

May 22, 2025 | businesswire.com

PureTech’s deupirfenidone shows strong and durable efficacy

May 21, 2025 | thepharmaletter.comT

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

May 9, 2025 | businesswire.com

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

May 1, 2025 | finance.yahoo.com

PureTech to Present Results from Phase 2b ELEVATE…

May 1, 2025 | pharmiweb.comP

PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript

April 30, 2025 | seekingalpha.com

PureTech Announces Annual Results for Year Ended December 31, 2024

April 30, 2025 | businesswire.com

PureTech Health Stock Price, Quotes and Forecasts | NASDAQ:PRTC | Benzinga

April 22, 2025 | benzinga.com

Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)

April 10, 2025 | markets.businessinsider.com

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

April 9, 2025 | businesswire.com

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

April 9, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, KOD, PGEN, and PRTC Company Descriptions

Kodiak Sciences NASDAQ:KOD

$8.62 +0.10 (+1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$8.62 0.00 (0.00%)

As of 05:10 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Precigen NASDAQ:PGEN

$1.91 +0.11 (+6.11%)

Closing price 04:00 PM Eastern

Extended Trading

$1.94 +0.03 (+1.31%)

As of 07:55 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Protalix BioTherapeutics NYSE:PLX

$1.61 -0.03 (-1.83%)

Closing price 04:00 PM Eastern

Extended Trading

$1.63 +0.02 (+1.18%)

As of 07:35 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

PureTech Health NASDAQ:PRTC

$17.74 +0.25 (+1.40%)

As of 04:00 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time